194 related articles for article (PubMed ID: 33268358)
1. BRAF inhibition protects against hearing loss in mice.
Ingersoll MA; Malloy EA; Caster LE; Holland EM; Xu Z; Zallocchi M; Currier D; Liu H; He DZZ; Min J; Chen T; Zuo J; Teitz T
Sci Adv; 2020 Dec; 6(49):. PubMed ID: 33268358
[TBL] [Abstract][Full Text] [Related]
2. Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI.
Pushpan CK; Kresock DF; Ingersoll MA; Lutze RD; Keirns DL; Hunter WJ; Bashir K; Teitz T
J Am Soc Nephrol; 2024 Jan; 35(1):22-40. PubMed ID: 37962623
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model.
Ingersoll MA; Lutze RD; Pushpan CK; Kelmann RG; Liu H; May MT; Hunter WJ; He DZ; Teitz T
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37934596
[TBL] [Abstract][Full Text] [Related]
4. CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.
Teitz T; Fang J; Goktug AN; Bonga JD; Diao S; Hazlitt RA; Iconaru L; Morfouace M; Currier D; Zhou Y; Umans RA; Taylor MR; Cheng C; Min J; Freeman B; Peng J; Roussel MF; Kriwacki R; Guy RK; Chen T; Zuo J
J Exp Med; 2018 Apr; 215(4):1187-1203. PubMed ID: 29514916
[TBL] [Abstract][Full Text] [Related]
5. Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Hazlitt RA; Teitz T; Bonga JD; Fang J; Diao S; Iconaru L; Yang L; Goktug AN; Currier DG; Chen T; Rankovic Z; Min J; Zuo J
J Med Chem; 2018 Sep; 61(17):7700-7709. PubMed ID: 30091915
[TBL] [Abstract][Full Text] [Related]
6. KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss.
Ingersoll MA; Lutze RD; Kelmann RG; Kresock DF; Marsh JD; Quevedo RV; Zuo J; Teitz T
bioRxiv; 2023 Nov; ():. PubMed ID: 38014104
[TBL] [Abstract][Full Text] [Related]
7. KSR1 Knockout Mouse Model Demonstrates MAPK Pathway's Key Role in Cisplatin- and Noise-induced Hearing Loss.
Ingersoll MA; Lutze RD; Kelmann RG; Kresock DF; Marsh JD; Quevedo RV; Zuo J; Teitz T
J Neurosci; 2024 May; 44(18):. PubMed ID: 38548338
[TBL] [Abstract][Full Text] [Related]
8. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
9. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
10. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
[TBL] [Abstract][Full Text] [Related]
12. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.
Hati S; Zallocchi M; Hazlitt R; Li Y; Vijayakumar S; Min J; Rankovic Z; Lovas S; Zuo J
Eur J Med Chem; 2021 Dec; 226():113849. PubMed ID: 34560429
[TBL] [Abstract][Full Text] [Related]
13. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss.
Wang J; Ladrech S; Pujol R; Brabet P; Van De Water TR; Puel JL
Cancer Res; 2004 Dec; 64(24):9217-24. PubMed ID: 15604295
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
15. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
16. Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy.
Benkafadar N; Menardo J; Bourien J; Nouvian R; François F; Decaudin D; Maiorano D; Puel JL; Wang J
EMBO Mol Med; 2017 Jan; 9(1):7-26. PubMed ID: 27794029
[TBL] [Abstract][Full Text] [Related]
17. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
18. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss.
Wang J; Van De Water TR; Bonny C; de Ribaupierre F; Puel JL; Zine A
J Neurosci; 2003 Sep; 23(24):8596-607. PubMed ID: 13679429
[TBL] [Abstract][Full Text] [Related]
19. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells.
Kurata K; Onoda N; Noda S; Kashiwagi S; Asano Y; Hirakawa K; Ohira M
Int J Oncol; 2016 Dec; 49(6):2303-2308. PubMed ID: 27748799
[TBL] [Abstract][Full Text] [Related]
20. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
